ALX Oncology Holdings Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALXO Nasdaq 2830 www.alxoncology.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ALX Oncology Holdings Inc.

ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer - Apr 13th, 2026 6:30 am
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA - Mar 18th, 2026 9:10 am
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data - Mar 17th, 2026 8:40 am
IBRX Stock Jumps on Progress in NK Cell Therapy Production - Mar 16th, 2026 11:35 am
JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study - Mar 16th, 2026 10:59 am
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 - Mar 13th, 2026 9:24 am
ALX Oncology initiated with a Buy at UBS - Mar 7th, 2026 6:25 am
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? - Mar 6th, 2026 8:26 am
Mirum Completes Enrollment & Screening in Liver Disease Studies - Mar 6th, 2026 6:27 am
ALX Oncology Highlights $150M Raise, Evorpacept Breast Cancer Push and EGFR ADC ALX2004 Update - Mar 3rd, 2026 9:34 pm
ALX Oncology Holdings Inc (ALXO) Q4 2025 Earnings Call Highlights: Strong Clinical Progress and ... - Feb 27th, 2026 2:04 pm
ALX Oncology Holdings Inc. Q4 2025 Earnings Call Summary - Feb 27th, 2026 10:31 am
ALX Oncology Q4 Earnings Call Highlights - Feb 27th, 2026 8:24 am
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Feb 27th, 2026 6:00 am
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026 - Feb 19th, 2026 6:33 am
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 - Feb 19th, 2026 6:30 am
3 Promising Penny Stocks With Market Caps Over $100M - Feb 10th, 2026 5:05 am
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? - Feb 9th, 2026 7:40 am
ALX Oncology Announces Pricing of Underwritten Offering - Jan 30th, 2026 6:30 am
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer - Jan 30th, 2026 6:15 am